MNKD
Price:
$6.84
Market Cap:
$1.89B
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect ...[Read more]
Industry
Biotechnology
IPO Date
2004-07-28
Stock Exchange
NASDAQ
Ticker
MNKD
According to MannKind Corporation’s latest financial reports and current stock price. The company's current ROE is -9.46%. This represents a change of 286.10% compared to the average of -2.45% of the last 4 quarters.
The mean historical ROE of MannKind Corporation over the last ten years is 56.65%. The current -9.46% ROE has changed -116.70% with respect to the historical average. Over the past ten years (40 quarters), MNKD's ROE was at its highest in in the December 2015 quarter at 79.07%. The ROE was at its lowest in in the September 2016 quarter at -53.01%.
Average
56.65%
Median
44.31%
Minimum
-68.45%
Maximum
268.92%
Discovering the peaks and valleys of MannKind Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 38.20%
Maximum Annual ROE = 268.92%
Minimum Annual Increase = -179.83%
Minimum Annual ROE = -68.45%
Year | ROE | Change |
---|---|---|
2023 | 4.85% | -89.17% |
2022 | 44.77% | 2.11% |
2021 | 43.85% | 38.20% |
2020 | 31.73% | 1.20% |
2019 | 31.35% | -36.89% |
2018 | 49.68% | -9.09% |
2017 | 54.64% | -179.83% |
2016 | -68.45% | -165.08% |
2015 | 105.17% | -60.89% |
2014 | 268.92% | -56.87% |
The current ROE of MannKind Corporation (MNKD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
31.16%
5-year avg
31.31%
10-year avg
56.65%
MannKind Corporation’s ROE is less than BioMarin Pharmaceutical Inc. (6.22%), greater than Vaxcyte, Inc. (-23.53%), greater than Liquidia Corporation (-155.77%), greater than Legend Biotech Corporation (-29.69%), less than Bio-Techne Corporation (7.36%), less than United Therapeutics Corporation (19.22%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Kiniksa Pharmaceuticals, Ltd. (-2.08%), greater than Verastem, Inc. (-212.61%), less than ImmunoGen, Inc. (5.04%), greater than Immutep Limited (-42.11%), greater than Intercept Pharmaceuticals, Inc. (-12.41%), greater than Elevation Oncology, Inc. (-59.73%), less than Acer Therapeutics Inc. (0%), less than NRx Pharmaceuticals, Inc. (56.36%), less than Pasithea Therapeutics Corp. (127.35%), greater than SAB Biotherapeutics, Inc. (-15595.10%), greater than MiNK Therapeutics, Inc. (-94.37%), less than Affimed N.V. (13.24%), greater than Adaptimmune Therapeutics plc (-193.85%), greater than Sangamo Therapeutics, Inc. (-74.84%), greater than null (-266.47%),
Company | ROE | Market cap |
---|---|---|
6.22% | $12.25B | |
-23.53% | $11.04B | |
-155.77% | $901.38M | |
-29.69% | $7.51B | |
7.36% | $11.33B | |
19.22% | $16.65B | |
-35.87% | $393.05M | |
-22.40% | $1.38B | |
-2.08% | $1.54B | |
-212.61% | $178.03M | |
5.04% | $8.73B | |
-42.11% | $280.00M | |
-12.41% | $794.69M | |
-59.73% | $35.67M | |
0% | $0 | |
56.36% | $14.63M | |
127.35% | $3.93M | |
-15595.10% | $28.89M | |
-94.37% | $26.89M | |
13.24% | $39.90M | |
-193.85% | $176.64M | |
-74.84% | $392.26M | |
-266.47% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MannKind Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MannKind Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is MannKind Corporation's ROE?
How is the ROE calculated for MannKind Corporation (MNKD)?
What is the highest ROE for MannKind Corporation (MNKD)?
What is the 3-year average ROE for MannKind Corporation (MNKD)?
What is the 5-year average ROE for MannKind Corporation (MNKD)?
How does the current ROE for MannKind Corporation (MNKD) compare to its historical average?